RankAlpha logo
Back to Rankings

PTGX

Protagonist TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
View Chart
Current thesis
The strongest current pro-thesis evidence is primary-source based: ICOTYDE is now approved and monetizable, while the rusfertide opt-out election reduces Protagonist's U.S. launch burden and increases milestone-plus-royalty leverage if approval arrives in Q3 2026 [#PR-2026-03-18] [#PR-2026-04-28].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +8.3.
What can break
ICOTYDE is approved, but royalty and milestone realization still depends on Johnson & Johnson launch execution and additional indication progress.
Momentum
88
Value
48
Sentiment
23
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $107.00 · Bull $125.00 · Bear $72.00
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-21 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $133.77
Why
Momentum88 · Δ7d +8.3
Value48 · Δ7d -0.0
Sentiment23 · Δ7d -4.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
88
26% active weight
Current posture
7d trendFlat
Δ7d
+8.3
Δ21d
+8.2
Value
48
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.2
Sentiment
23
34% active weight
Current posture
7d trendSoftening
Δ7d
-4.3
Δ21d
-11.4
Why this grade

Composite grade C. Momentum 88.5 / Value 48.4 / Sentiment 23.4

Fundamentals (TTM)
As of 2026-07-21
Market Cap
$8.89B
Beta
2.27
Shares Out
64.31M
P/E (TTM)
133.3
P/S (TTM)
25.15
P/FCF (TTM)
82.60
Rev YoY
+99.0%
EPS YoY
-129.0%
Gross Margin
+98.0%
Op Margin
+9.1%
Net Debt
-$557.04M
Current Ratio
17.76
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology